Table 1.
Baseline demographics and clinicopathological characteristics of Asian patients with ESCC
| Characteristic | Asian subgroup N = 221 |
China cohort N = 119 |
||
|---|---|---|---|---|
| Pembrolizumab n = 110 | Chemotherapy n = 111 | Pembrolizumab n = 60 | Chemotherapy n = 59 | |
| Age, years, median (range) | 66.0 (45-80) | 64.0 (33-84) | 61.5 (45-74) | 59.0 (41-77) |
| Male | 100 (90.9) | 97 (87.4) | 55 (91.7) | 56 (94.9) |
| ECOG PS | ||||
| 0 | 56 (50.9) | 51 (45.9) | 9 (15.0) | 6 (10.2) |
| 1 | 54 (49.1) | 60 (54.1) | 51 (85.0) | 53 (89.8) |
| PD-L1 CPS | ||||
| ≥1 | 89 (80.9) | 90 (81.1) | 50 (83.3) | 51 (86.4) |
| <1 | 19 (17.3) | 21 (18.9) | 8 (13.3) | 7 (11.9) |
| ≥5 | 71 (64.5) | 72 (64.9) | 32 (53.3) | 37 (62.7) |
| <5 | 37 (33.6) | 39 (35.1) | 26 (43.3) | 21 (35.6) |
| ≥10 | 57 (51.8) | 54 (48.6) | 24 (40.0) | 28 (47.5) |
| <10 | 51 (46.4) | 57 (51.4) | 34 (56.7) | 30 (50.8) |
| Nonassessablea | 2 (1.8) | 0 (0) | 2 (3.3) | 1 (1.7) |
| Previous (neo)adjuvant therapy | 13 (11.8) | 15 (13.5) | 11 (18.3) | 12 (20.3) |
| Disease stage | ||||
| Metastatic | 97 (88.2) | 102 (91.9) | 57 (95.0) | 55 (93.2) |
| Locally advanced | 13 (11.8) | 9 (8.1) | 3 (5.0) | 4 (6.8) |
| Previous therapies | ||||
| One previous therapyb | 108 (98.2) | 110 (99.1) | 60 (100) | 59 (100) |
| Previous anthracycline | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Previous fluoropyrimidine | 106 (96.4) | 105 (94.6) | 20 (33.3) | 21 (35.6) |
| Previous taxane | 32 (29.1) | 35 (31.5) | 45 (75.0) | 53 (89.8) |
Data are presented as number (%) unless indicated otherwise. Patients in the chemotherapy group received investigator's choice of paclitaxel, docetaxel, or irinotecan. Patients in the Asian subgroup do not include Chinese patients. Percentages may not total 100 because of rounding.
CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; ESCC, esophageal squamous cell carcinoma; PD-L1, programmed death-ligand 1.
PD-L1 expression could not be evaluated because samples had inadequate numbers of cells or no cells.
Three patients in the Asian subgroup previously received one or two lines of therapy (n = 2, pembrolizumab; n = 1, chemotherapy).